Cerus Corporation 2022 Q1 Form 10-Q Summary
Business context and reporting period
Cerus Corporation is a blood-safety company focused on the INTERCEPT Blood System for pathogen reduction of platelets and plasma, cryoprecipitation products, and the development of a red blood cell system. The company operates in one blood-safety segment. This unaudited report covers the three months ended March 31, 2022, compared with the same period in 2021.
Financial performance and key metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Product revenue | $37.4 million | $23.4 million | Up 60% |
| Government contract revenue | $5.6 million | $6.2 million | Down 10% |
| Total revenue | $43.0 million | $29.6 million | Up 46% |
| Gross profit on product revenue | $19.4 million | $12.3 million | Up 58% |
| Product gross margin | Approximately 52% | Approximately 53% | Down approximately 1 point |
| Loss from operations | $(9.8) million | $(16.4) million | Improved $6.6 million |
| Net loss attributable to Cerus | $(12.3) million | $(17.5) million | Improved $5.2 million |
| Net loss per share | $(0.07) | $(0.10) | Improved |
| Net cash used in operating activities | $(21.5) million | $(17.5) million | Higher use of $4.0 million |
Product revenue growth was primarily driven by higher U.S. disposable platelet-system kit sales. North American product revenue increased to $22.2 million from $9.7 million, while Europe, the Middle East and Africa contributed $14.8 million versus $13.3 million. Product gross margin was pressured by geographic and product mix, higher freight costs, foreign exchange effects and supply-chain costs.
Research and development expense declined 11% to $14.1 million, primarily because certain prior-year projects were completed and government-contract activity decreased. Selling, general and administrative expense increased 8% to $20.7 million due mainly to hiring and higher stock-based compensation. Interest expense increased to $1.4 million from $1.0 million, largely reflecting the additional $15.0 million term-loan tranche drawn in March 2021. Other expense was $0.8 million compared with other income of $0.5 million in the prior year, primarily reflecting unfavorable changes in investment values.
Liquidity, capital resources and debt
| Balance-sheet item | March 31, 2022 | December 31, 2021 |
|---|---|---|
| Cash and cash equivalents | $38.4 million | $48.8 million |
| Short-term investments | $70.2 million | $80.6 million |
| Restricted cash | $2.0 million | $2.3 million |
| Total liquidity, including restricted cash | $110.6 million | $131.6 million |
| Working capital | $106.2 million | $108.5 million |
| Total debt | $69.8 million | $69.4 million |
Cash, cash equivalents and restricted cash decreased by $10.7 million during the quarter. Operating activities used $21.5 million, partially offset by $8.6 million of net investing inflows and $2.4 million of financing inflows. Management stated that available cash, short-term investments, product-sale receipts and government-contract receipts are expected to meet capital requirements for at least the next 12 months, but this assessment depends on assumptions that may prove incorrect.
Debt consisted of a $55.0 million term loan and $15.0 million drawn under a revolving facility, with approximately $69.8 million net carrying value. The term loan matures March 1, 2024, bears an effective interest rate of approximately 7.50% at quarter-end, and requires interest-only payments through March 1, 2023, followed by principal amortization. The debt facilities are secured by substantially all company assets and include financial and non-financial covenants; the company reported compliance at March 31, 2022.
Material changes, outlook and unusual items
- Product revenue accelerated substantially, led by U.S. platelet-kit volume growth, while government-contract revenue declined modestly.
- Operating and net losses narrowed despite increased operating cash consumption, reflecting higher product revenue and gross profit.
- Management expects continued product-revenue growth from U.S. expansion, broader INTERCEPT adoption and future IFC sales, but does not expect government-contract revenue to materially change from historical trends.
- The company expects additional R&D and commercialization spending for the red blood cell system, IFC, product enhancements, the next-generation illuminator, regulatory activities and clinical studies.
- The red blood cell system remains uncommercialized and requires further regulatory and clinical progress. The company did not expect a European certification decision for at least another 12 months, if ever, and identified a dispute with a key component supplier that could further delay approval.
- BARDA had committed up to $126.5 million as of March 31, 2022, with potential total funding of up to $223.5 million through December 31, 2023 if additional options are exercised. The additional funding is discretionary, and BARDA may terminate the agreement for convenience. Certain options could require up to $9.6 million of company co-investment.
- COVID-19 continued to affect customer access, clinical-trial enrollment, government-funded activities, supply chains and hospital implementation. Inflation, higher transportation and supplier costs, rising interest rates, foreign-exchange volatility and the Russia-Ukraine conflict were also identified as risks.
- The company had $23.4 million of short-term and $2.7 million of long-term purchase commitments for INTERCEPT components that were not recorded on the balance sheet.
- In May 2022, after the reporting date, Cerus signed a ten-year extension with Fresenius to manufacture and supply INTERCEPT sets and expand production at additional sites. The company was still assessing the accounting and financial-statement impact.
- An immaterial comparative-period cash-flow classification error was corrected, reducing reported Q1 2021 operating cash use by approximately $0.5 million with a corresponding separate exchange-rate effect.
Key risks and contingencies
- Continued losses and negative operating cash flow may require additional debt, equity or government funding. Equity financing could dilute shareholders.
- Commercial success depends heavily on adoption of INTERCEPT in the concentrated U.S. blood-collection market, including continued utilization by major customers.
- The company relies on Fresenius and other third parties, including sole or limited-source suppliers, for manufacturing and critical components. Supply interruptions, obsolescence, nonconformities or capacity constraints could reduce sales and margins.
- The current illuminator is being phased out because of component obsolescence. A redesigned illuminator requires supplier validation and regulatory approval, creating potential supply and revenue constraints.
- Clinical trials for the red blood cell system have experienced COVID-19-related and other enrollment delays, and regulatory approval is uncertain. The filing notes antibody events in the RedeS and ReCePI studies without evidence of hemolysis and warns that additional events could affect development.
- Product sales and costs are exposed to foreign-currency movements, particularly the euro; the company does not maintain a formal hedging program.
- Debt covenants, secured collateral, variable-rate exposure tied to LIBOR and 2024 maturities may constrain financial flexibility.
Facts investors should verify
- Whether U.S. platelet-kit volume growth and the approximately 52% product gross margin are sustainable after mix, freight, inflation and supply-chain effects.
- The company’s cash-burn trajectory relative to the stated expectation that liquidity will fund at least the next 12 months.
- Progress, enrollment and safety results for the RedeS and ReCePI trials and the timing and outcome of European red blood cell certification.
- Whether BARDA exercises additional options, maintains funding and provides extensions sufficient to complete planned development activities.
- Fresenius production expansion, resolution of the key-component supplier dispute and availability of the redesigned illuminator.
- The financial impact of the ten-year Fresenius supply agreement signed in May 2022 and the commercial ramp of IFC.
- Customer concentration, including the American Red Cross at 35% and Établissement Français du Sang at 13% of Q1 2022 product revenue.